Those results were presented at the World Conference on Lung Cancer of the International Association for the Study of Lung Cancer meeting in Amsterdam, the Netherlands

Synta Pharmaceuticals Corp., of Lexington, Mass., reported results showing that ganetespib (STA-9090), a heat-shock protein 90 inhibitor, was more potent than 17-AAG and was synergistic with doxorubicin in a model of small-cell lung cancer...Data were presented at the International Association for the Study of Lung Cancer meeting in Amsterdam, the Netherlands

Ariad Pharmaceuticals Inc., of Cambridge, Mass., said its non-small-cell lung cancer candidate, AP26113, showed targeted inhibition of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) in cell culture and mouse models following once-daily dosing...The drug has potential for EGFR-mutant lung cancer as well

The vaccine, known as SCIB2, stimulates immune responses to the lung cancer antigen NY-ESO-1 and may also have potential utility in esophageal, liver, gastric, prostate, ovarian and bladder cancers

The vaccine, known as SCIB2, stimulates immune responses to the lung cancer antigen NY-ESO-1 and may also have potential utility in esophageal, liver, gastric, prostate, ovarian and bladder cancers

The suit was related to statements made regarding lung cancer drug NOV-002 before it failed a Phase III trial. (See BioWorld Today, Feb. 25, 2010

Ariad Pharmaceuticals Inc., of Cambridge, Mass., said results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor, AP26113, showed it has a novel profile as a dual inhibitor of ALK and epidermal growth factor receptor (EGFR), an additional validated target in non-small-cell lung cancer

It will pursue MGCD265 in non-small-cell lung cancer, gastric cancer and prostate cancer, with enrollment beginning in the third quarter

In separate news, Avila said it achieved a goal is its alliance with Clovis Oncology Inc., of Boulder, Colo., having selected an epidermal growth factor receptor mutant-selective inhibitor drug candidate to advance into clinical development in non-small-lung cancer

Data from a Phase II study in combination with cisplatin-based chemotherapy showed evidence of improved activity in terms of disease control and duration of progression-free survival in first-line non-small-cell lung cancer patients, while top-line results from a Phase II trial of NGR-hTNF in combination with doxorubicin produced disease control in more than half of the 28 relapsed NSCLC patients enrolled, with a third of patients progression-free at six months and alive at one year

Clovis Oncology Inc., of Boulder, Co., will partner with Roche AG, of Basel, Switzerland, to develop a PCR-based companion diagnostic test for epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer

Agennix AG, of Planegg, Germany, said Phase II data published in the Journal of Thoracic Oncology showed that oral talactoferrin increased the confirmed response rate compared to placebo in non-small-cell lung cancer patients...Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, of Ingelheim, Germany, said new Phase Ib data indicated that combining investigational therapy afatinib (BIBW 2992) with cetuximab at the maximum tested dose controlled

Proceeds will enable the firm to continue with further research and development of programs based on DNA-directed RNA interference technology, including advancing its chronic cancer-associated pain and drug-resistant lung cancer programs to Phase I/II and moving its hepatitis B program to completion of preclinical and toxicology studies...The data from an in vivo model of metastatic lung cancer were presented at the annual meeting of the American Society of Gene & Cell Therapy in Seattle

The data from an in vivo model of metastatic lung cancer were presented Thursday at the annual meeting of the American Society of Gene & Cell Therapy in Seattle

Polaris and LICR previously collaborated on ADI-PEG 20 in melanoma and are conducting a Phase II trial in small-cell lung cancer

Pfizer Inc., of New York, reported that its new drug application for crizotinib, an oral anaplastic lymphoma kinase (ALK) inhibitor, has been accepted for filing and granted priority review status by the FDA and has been filed with the Japanese Ministry of Health, Labour and Welfare for treatment of patients with ALK-positive advanced non-small-cell lung cancer

Ltd., of Tokyo, started enrolling patients in a Phase III European trial of tivantinib (ARQ 197), a c-MET receptor tyrosine kinase inhibitor, in advanced nonsquamous non-small-cell lung cancer

Biotech Synergy, of Encino, Calif., concluded an asset transfer of a cancer vaccine, previously known as EP-2101, and other cancer epitope products from Epimmune Inc. (now merged with Cytel Inc., of Cambridge, Mass.) In a Phase II trial of EP-2101, one-year survival in patients with HLA-A2 positive non-small-cell lung cancer was improved 60 percent, compared to 49 percent in patients who were HLA-A2 negative but otherwise comparable...The case study documented total elimination of promyelocytic

Three other trials provided new data on Irvalec, a marine-based synthetic depsipeptide in Phase II for lung cancer...The first evaluated the modulation of initial cytotoxic effects of Irvalec using zinc and DIDS in lung cancer cells, suggesting plasma membrane damage caused by Irvalec generates a rapid onset of hydroelectrolyte imbalance, leading to cell death by necrosis